EESM:F:F-BNP Paribas Easy - MSCI Europe Small Caps ex Controversial Weapons (EUR)

ETF | Others |

Last Closing

USD 292.25

Change

-2.55 (-0.86)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.03 (-0.09%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.05 (+0.10%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.60 (+0.25%)

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.05B
VUSA:F Vanguard Funds Public Limited ..

+0.24 (+0.24%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.28 (+0.28%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.74B
0ZC:F Zscaler Inc

-3.78 (-2.48%)

USD 37.92B

ETFs Containing EESM:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.22% 49% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.22% 45% F 50% F
Trailing 12 Months  
Capital Gain 24.65% 74% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.65% 70% C- 60% D-
Trailing 5 Years  
Capital Gain 29.92% 51% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.92% 51% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 6.18% N/A N/A 61% D-
Dividend Return 6.18% N/A N/A 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.91% N/A N/A 62% D
Risk Adjusted Return 29.54% N/A N/A 55% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike